Jeffrey D. Bradley

Professor and Vice Chair

Hospital of the University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Year:

2026

Year:

2026

IntroductionAssessments of local control (LC) following stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) play a crucial role in evaluating treatment efficacy. However, there is significant variability in how LC is defined and assessed across studies, making it challenging to compare outcomes and establish standardized benchmarks. This heterogeneity impacts clinical decision-making, prognostic assessment, and the interpretation of lung SBRT efficacy in both research and clinical practice.MethodsA systematic review was conducted following PRISMA guidelines to identify criteria used in reporting post-SBRT local control (LC) rates. A comprehensive PubMed search identified studies published between 2006 and 2023 reporting LC or primary tumor control rates following SBRT for early-stage NSCLC. Eligible studies were independently reviewed, and LC definitions were categorized based on the anatomical sites considered and the criteria used to define relapse.ResultsOf 155 studies identified, 113 met the inclusion criteria. LC determinations were described as ‘local control’, ‘local failure’, ‘local recurrence’, or ‘primary tumor control’ in 39%, 32%, 24%, and 4% of studies, respectively. Anatomic sites assessed for LC included recurrence within the primary tumor site, same lobe, ipsilateral lung, and regional nodes in 68%, 11%, 4%, and 2%, respectively; 15% did not specify anatomical location. We identified 12 different criteria for LC and PTC evaluations, including requirements for a specific imaging modality (CT or PET), growth threshold (RECIST or up to 50% increase), minimum growth duration (2-36 months or serial changes), or histopathological confirmation in 28%, 31%, 18%, and 1%, respectively. LC rates included recurrence events occurring outside of the primary tumor site in 32% of publications.ConclusionsTo improve consistency and interpretability of SBRT outcomes, LC should be reported using standardized, treatment-site specific criteria. We recommend that LC be restricted to recurrence at the treatment-site, explicitly excluding same-lobe, ipsilateral lung, and nodal failures, which should be reported as separate endpoints. LC assessments should specify the imaging modality used, apply objective growth thresholds based on serial imaging rather than single time-point changes, and clearly define minimum duration for progression. Adoption of uniform terminology and anatomically precise definitions across studies is essential to enable valid cross-trial comparisons, support reliable meta-analyses, and ensure that SBRT efficacy is accurately represented in clinical guidelines and patient counseling.

Year:

2026

Year:

2025

PURPOSE Immunotherapy targeting PD-L1 improves outcomes in patients with unresectable stage III non–small cell lung cancer (NSCLC) and no progression after definitive, concurrent chemoradiotherapy (cCRT). Earlier administration of immunotherapy, simultaneously with cCRT, may improve outcomes further. METHODS Eligible patients were randomly assigned (2:1) to receive either durvalumab or placebo administered from the start of cCRT. Patients without progression after completing cCRT received consolidation durvalumab or placebo (per initial random assignment) until progression. The primary end point was progression-free survival (PFS) by blinded independent central review. Key secondary end points included objective response rate (ORR), overall survival (OS), the proportion of patients alive at 24 months (OS24), and safety. RESULTS In total, 328 patients were randomly assigned to receive durvalumab (n = 219) or placebo (n = 109). There was no statistically significant difference with durvalumab versus placebo in PFS (hazard ratio [HR], 0.85 [95% CI, 0.65 to 1.12]; P = .247) or OS (HR, 1.03 [95% CI, 0.78 to 1.39]; P = .823); OS24 was 58.4% versus 59.5%, respectively. Confirmed ORR was 60.7% with durvalumab versus 60.6% with placebo (difference, 0.2% [95% CI, −15.2 to 16.3%]; P = .976). With durvalumab versus placebo, respectively, maximum grade 3 or 4 adverse events (AEs) occurred in 53.4% versus 59.3% of patients, pneumonitis or radiation pneumonitis (group term) in 28.8% (grade ≥3: 4.6%) versus 28.7% (grade ≥3: 5.6%), AEs leading to discontinuation of durvalumab or placebo in 25.6% versus 12.0%, and fatal AEs in 13.7% versus 10.2%. CONCLUSION Among patients with unresectable stage III NSCLC, durvalumab administered from the start of cCRT failed to demonstrate additional benefit compared with cCRT plus placebo. Consolidation durvalumab following definitive cCRT remains the standard of care in this setting.

Year:

2025

We present the results of a randomized, open-label pilot study investigating the combination of oral vancomycin and stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC). Our findings highlight vancomycin’s safety, evidenced by the absence of Grade 3 or 4 adverse events, and its potential to enhance the antitumor efficacy of SBRT. The observed enhancement is linked to vancomycin’s modulation of the gut microbiota, which triggers significant metabolic changes and immune activation, thereby contributing to improved progression-free survival (PFS) and overall survival (OS). Patients received vancomycin (125 mg, four times daily for five weeks, starting one week prior to SBRT), which induced restructuring of the gut microbiome and significant changes in the gut metabolome. Key changes included reductions in short-chain fatty acids (SCFAs) and shifts in other immunomodulatory metabolites. These metabolic shifts were associated with the activation of dendritic cells and T cells, creating a pro-inflammatory environment conducive to strengthening SBRT’s antitumor efficacy. The combination of vancomycin and SBRT presents a novel, low-toxicity therapeutic approach for early-stage NSCLC, showing promising initial outcomes. While the results are encouraging, further research with larger cohorts is necessary to verify these findings and elucidate the underlying mechanisms that contribute to the observed clinical benefits. WHAT IS ALREADY KNOWN ON THIS TOPIC Radiation therapy is a primary treatment for early-stage non-small cell lung cancer and offers excellent local control in early-stage NSCLC, the challenges of regional and distant failures which occur in up to 50% of patients, lead to increased morbidity and mortality. The gut microbiome is increasingly recognized in cancer immunotherapy. RT can induce Immunogenic Cell Death, activating the immune system and promoting abscopal effect to impact untreated lesions. Our previous preclinical studies have shown that antibiotics like vancomycin can modulate these immune effects and enhance RT’s antitumor activity. WHAT THIS STUDY ADDS This clinical study corroborates our previous preclinical findings by demonstrating the safety of vancomycin and its potential to enhance the antitumor effects of RT, despite the small cohort size. These findings suggest that vancomycin could be strategically used to improve RT outcomes. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Our findings prompt further investigation into this combined treatment in a larger patient cohort to confirm enhanced progression-free survival and overall survival. Exploring the impact on distal recurrences and applying this strategy to more advanced patient stages could significantly influence future research directions and clinical practices. This approach may also guide policy towards integrating microbiome modulation strategies in standard cancer treatment protocols.

Year:

2025

Year:

2022

Collaborators (16)

David A. Palma

Western University

CANADA
View details

Amit Maity

Professor and Chair of Dept. of Radiation Oncology

University of Utah

UNITED STATES
View details

Chen Hu

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Sanjay Popat

Reader

Institute of Cancer Research

UNITED KINGDOM
View details

Matthias Guckenberger

Chairman

University Hospital of Zurich

SWITZERLAND
View details

Roddy S. O'Connor

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Shankar Siva

University of Melbourne

AUSTRALIA
View details

Francesca Costabile

University of Pennsylvania

UNITED STATES
View details

Kristof Cuppens

Hasselt University

BELGIUM
View details

Suresh Senan

Professor of clinical experimental radiotherapy

Amsterdam University Medical Centers

NETHERLANDS
View details

Shane Lloyd

-

UNITED STATES
View details

Kyle Bittinger

Children's Hospital of Philadelphia

UNITED STATES
View details

Divyansh Agarwal

University of Minnesota

UNITED STATES
View details

Sue S. Yom

University of California, San Francisco

UNITED STATES
View details

Costas Koumenis

Richard H. Chamberlain Professor with Tenure

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Andrea Facciabene

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details